GLENMARK - IntraDay Trade Analysis with Live Signals

Last Updated Time : 20 Dec 25, 07:02 am

IntraDay Trade Rating: 3.6

📊 Analysis: GLENMARK shows moderate intraday potential. Current price (₹1,991) is above both the 50 DMA (₹1,925) and 200 DMA (₹1,804), reflecting short-term strength. RSI at 55.4 indicates neutral-to-slightly bullish momentum, while MACD (19.6) confirms positive momentum. Volume (3.65 lakh) is in line with the weekly average (3.68 lakh), showing stable participation. However, sharp quarterly profit decline (-67.6%) raises caution for sustained upside.

💡 Optimal Buy Price: ₹1,985–₹1,995 (near support zone).

🎯 Profit Exit Levels: ₹2,030 (first resistance), ₹2,070 (second resistance).

🛡️ Stop-Loss: ₹1,960 (below intraday support).

⏱️ If Already Holding: Exit intraday if price fails to sustain above ₹1,991 or if momentum weakens despite positive MACD. Consider booking profits near ₹2,030–₹2,070 if intraday momentum improves.

Positive

• 📈 Price above DMA levels indicates short-term strength.
• 💰 Low debt-to-equity (0.02) ensures financial stability.
• 📊 DII holding increased (+0.97%), showing domestic investor confidence.
• 🌍 FII holding increased (+0.11%), reflecting foreign investor support.

Limitation

• ⚠️ Quarterly PAT dropped from ₹596 Cr. to ₹193 Cr. (-67.6%).
• 📉 ROCE (9.72%) and ROE (7.35%) show weak capital efficiency.
• 📊 High PEG ratio (19.1) signals expensive growth prospects.
• 📉 Dividend yield (0.13%) provides limited shareholder returns.

Company Negative News

• 📰 No major negative news reported, but sharp profit decline weighs heavily on sentiment.

Company Positive News

• 📰 Stable EPS (₹5.41) and price strength above DMA levels support near-term confidence.
• 📊 Institutional inflows from both FII and DII add support.

Industry

• 🏭 Pharma sector trading at PE 30.6, lower than GLENMARK’s valuation (38.2).
• 📈 Industry demand supported by healthcare expansion and global pharma exports.

Conclusion

⚖️ GLENMARK is fundamentally stable with institutional support and price strength above DMA levels, but faces weak profitability and high valuation concerns. Intraday trading opportunity exists with cautious entry near ₹1,985–₹1,995 and profit exits at ₹2,030–₹2,070, while maintaining a strict stop-loss at ₹1,960.

Would you like me to extend this into a peer benchmarking overlay comparing GLENMARK with other pharma mid-cap stocks, or should we focus on basket rotation signals for intraday workflow optimization?